Medical and economic impact of extraintestinal infections due to Escherichia coli: Focus on an increasingly important endemic problem

Microbes and Infection

Volumn 5, Issue 5, 2003, Pages 449-456

  Russo, Thomas A ^a   Johnson, James R ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Antibiotic resistance; Costs; Economics; Extraintestinal Escherichia coli infections; Incidence of infection; Mortality; Sepsis; Urinary tract infection

Indexed keywords

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL PERITONITIS; BACTERIAL STRAIN; COMMENSALISM; ECONOMIC ASPECT; ENDEMIC DISEASE; ENTEROPATHY; ESCHERICHIA COLI; HEALTH CARE COST; HUMAN; INFECTION RATE; MENINGITIS; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SEPSIS; SURGICAL INFECTION; URINARY TRACT INFECTION;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 0038076041     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(03)00049-2     Document Type: Review

References (72)

1. Russo T., Johnson J. A proposal for a new inclusive designation for extraintestinal pathogenic isolates of Escherichia coli: ExPEC. J. Infect. Dis. 181:2000;1753-1754.
2. Nataro J.P., Kaper J.B. Diarrheagenic Escherichia coli. Clin. Microbiol. Rev. 11:1998;142-201.
3. Tarr P., Fouser L., Stapleton A., et al. Hemolytic-uremic syndrome in a six-year-old girl after a urinary tract infection with Shiga-toxin-producing Escherichia coli O103:H2. New Engl. J. M. 335:1996;635-638.
4. Johnson J., Stell A. Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise. J. Infect. Dis. 181:2000;261-272.
5. Picard B., Sevali-Garcia J., Gouriou S., et al. The link between phylogeny and virulence in Escherichia coli extraintestinal infection. Infect. Immun. 67:1999;546-553.
6. Johnson J., Kuskowski M., O'Bryan T., Maslow J. Epidemiologic correlates of virulence genotype and phylogenetic background among Escherichia coli blood isolates from adults with diverse-source bacteremia. J. Infect. Dis. 185:2002;1439-1447.
7. Soriano G., Coll P., Guarner C., et al. Escherichia coli capsular polysaccharide and spontaneous bacterial peritionitis. Hepatology. 21:1995;668-673.
8. Johnson J., Russo T. Extraintestinal pathogenic Escherichia coli (ExPEC): The 'other bad E. coli'. J. Lab. Clin. M. 139:2002;155-162.
9. Johnson J., Russo T. "Uropathogenic" Escherichia coli as agents of diverse non-urinary-tract extraintestinal infections. J. Infect. Dis. 186:2002;859-864.
10. McBean M., Rajamani S. Increasing rates of hospitalization due to septicemia in the US elderly population, 1986-1997. J. Infect. Dis. 183:2001;596-603.
11. Gransden W., Eykyn S., Phillips I., Rowe B. Bacteremia due to Escherichia coli: A study of 861 episodes. Rev. Infect. Dis. 12:1990;1008-1018.
12. Roberts F., Geere I., Coldman A. A three-year study of positive blood cultures, with emphasis on prognosis. Rev. Infect. Dis. 13:1991;34-46.
13. Vastag B. New vaccine decreases rate of nosocomial infections. J. Am. Med. Assoc. 285:2001;1565.
14. Hooton T., Stamm W. Diagnosis and treatment of uncomplicated urinary tract infection. Infect. Dis. Clin. North Am. 11:1997;551-581.
15. Stamm W., Hooton T. Management of urinary tract infection in adults. New Engl. J. M. 329:1993;1328-1334.
16. Harding G., Ronald A. The management of urinary tract infections: what we have learned in the last decade. Int. J. Antimicrob. Agents. 4:1994;83-88.
17. Schappert S. National ambulatory medical care survey: 1992 survey. Hyattsville, MD, DHHS publication no. (PHS) 94-1250. 1994;. (advanced data for vital and health statistics. No. 253).
18. Patton J., Nash D., Abrutyn E. Urinary tract infection: economic considerations. Med. Clin. North Am. 75:1991;495-513.
19. Foxman B., Frerichs R. Epidemiology of urinary tract infection. 1. Diaphragm use and sexual intercourse. Am. J. Public Health. 75:1985;1308-1313.
20. Talan D., Stamm W., Hooton T., et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. J. Am. Med. Assoc. 283:2000;1583-1590.
21. McCarthy E. Inpatient utilization of short-stay hospitals, by diagnosis: United States-1980. DHHS publication no. (PHS) 83-1735. 1980;National Center for Health Statisitcs, Hyattsville, MD.
22. Stamm W., Hooton T., Johnson J., et al. Urinary tract infections. J. Infect. Dis. 15:1989;400-406.
23. Fluit A., Schmitz F., Verhoef J. Frequency of isolation of pathogens from bloodstream, nosocomial pneumonia, skin and soft tissue, and urinary tract infections occurring in European patients. Eur. J. Clin. Microbiol. Infect. Dis. 20:2001;188-191.
24. Stamm W. Catheter-associated urinary tract infections: epidemiology, pathogenesis, and prevention. Am. J. M. 91:(3B):1991;65S-71S.
25. Saint S. Clinical and economic consequences of nosocomial catheter-related bacteriuria. Am. J. Infect. Control. 28:2000;68-75.
26. Muder R. Pneumonia in residents of long-term care facilities: epidemiology, etiology, management, and prevention. Am. J. M. 105:1998;319-330.
27. Emori T., Gaynes R. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin. Microbiol. Rev. 6:1993;428-442.
28. Craven D., Barber T., Steger K., Montecalvo M. Nosocomial pneumonia in the 1990s: update of epidemiology and risk factors. Semin. Respir. Infect. 5:1990;157-172.
29. CDC NNIS System, National nosocomial infections surveillance (NNIS) report, data summary from October 1986 to April 1996, issued May 1996. Am. J. Infect. Control. 24:1996;380-388.
30. Dal Nogare A. Nosocomial pneumonia in the medical and surgical patient. Med. Clin. North Am. 78:1994;1081-1090.
31. Wenzel R. Hospital-acquired pneumonia: overview of the current state of art for prevention and control. Eur. J. Clin. Microbiol. 8:1989;56-60.
32. Horan T., Culver D., Jarvis W. Pathogens causing nosocomial infections. Antimicrob. Newslett. 5:1988;65-67.
33. Cook D., Guyatt G., Marshall J., et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. New Engl. J. M. 338:1998;791-797.
34. Jarvis W. Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention. Infect. Control Hosp. Epidemiol. 17:1996;552-557.
35. Hyattsville, MD. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health StatisticsVital and Health statistics, Ambulatory and in-patient procedures in the United States, 1995. Series 13: data from the national health care survey, no. 135, DHHS publication no. (PHS) 98-1796. Hyattsville, MD. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, 1998.
36. Poulsen K., Wachmann C., Bremmelgaard A., et al. Survival of patients with surgical wound infection: a case-control study of common surgical interventions. Br. J. Surg. 82:1995;208-209.
37. Kirkland K., Briggs J., Trivette S., Wilkinson W., Sexton D. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect. Control Hosp. Epidemiol. 20:1999;725-730.
38. Zoutman D., McDonald S., Vethanayagan D. Total and attributable costs of surgical-wound infections at a Canadian tertiary-care center. Infect. Control Hosp. Epidemiol. 19:1998;254-259.
39. De Louvois J. Acute bacterial meningitis in the newborn. J. Antimicrob. Chemother. 34:(Suppl. A):1994;61-73.
40. Murphy S. Deaths: Final Data for 1998. National Vital Statistics Reports 48. 2000.
41. Stoll B., Hansen N., Fanaroff A., et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. New Engl. J. M. 347:2002;240-247.
42. Franco S., Cornelius V., Andrews B. Long-term outcome of neonatal meningitis. Am. J. Dis. Child. 146:1992;567-571.
43. Unhanand M., Mustafa M., McCracken G., Nelson J. Gram-negative enteric bacillary meningitis: a twenty-year experience. J. Pediatr. 122:1993;15-21.
44. Pauwels A., Pines E., Abboura M., Chiche I., Levy V.G. Bacterial meningitis in cirrhosis: review of 16 cases. J. Hepatol. 27:1997;830-834.
45. Revathi G., Puri J., Jain B. Bacteriology of burns. Burns. 24:1998;347-349.
46. Saccente M. Periprosthetic joint infections: a review for clinicians. Infect. Dis. Clin. Pract. 7:1998;431-441.
47. Sapico F. Pyogenic hematogenous spinal infections. Infect. Dis. Clin. Pract. 8:1999;267-269.
48. Elliott D., Kufera J., Myers R. The microbiology of necrotizing soft tissue infections. Am. J. Surg. 179:2000;361-366.
49. Grayson M., Gibbons G., Habershaw G., et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin. Infect. Dis. 18:1994;683-693.
50. Bernard G., Vincent J., Laterre P., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. New Engl. J. M. 344:2001;699-709.
51. Siegman-Igra Y., Fourer B., Orni-Wasserlauf R., et al. Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia. Clin. Infect. Dis. 34:2002;1431-1439.
52. Olesen B., Kolmos H.J., Orskov F., Orskov I., Gottschau A. Bacteraemia due to Escherichia coli in a Danish university hospital, 1986-1990. Scand. J. Infect. Dis. 27:1995;253-257.
53. Ismail N., Lieu P., Lien C., Ling M. Bacteremia in the elderly. Ann. Acad. Med. Singapore. 26:1997;593-598.
54. Sader H., Jones R., Andrade-Baiocchi S., Biedenbach D. Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers. Diagn. Microbiol. Infect. Dis. 44:2002;273-280.
55. Gosbell I., Newton P., Sullivan E. Survey of blood cultures from five community hospitals in south-western Sydney, Australia, 1993-1994. Aust. New Zealand J. M. 30:2000;684-692.
56. McGregor A., Colligan P. Bacteraemia and fungaemia in an Australian general hospital-associations and outcomes. Med. J. Aust. 158:1993;671-674.
57. Elhanan G., Raz R., Pitlik S., et al. Bacteraemia in a community and a university hospital. J. Antimicrob. Chemother. 36:1995;681-695.
58. Rayner B., Willcox P. Community-acquired bacteraemia; a prospective survey of 239 cases. Q. J. M. 69:1988;907-919.
59. American College of Chest Physicians-Society of Critical Care Medicine Consensus Conference, Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care M. 20:1992;864-875.
60. Minino A., Smith B. Deaths: Preliminary data for 2000. National Vital Statistics Reports. 49:2001;1-40.
61. Angus D., Linde-Zwirble W., Lidlicker J., Clermont G., Carcillo J., Pinsky M. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care M. 29:2001;1303-1310.
62. The world health report 2000-health systems: improving performance. 2000;World Health Organization, Geneva.
63. Gupta K., Hooton T., Stamm W. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann. Intern. M. 135:2001;41-50.
64. Gupta K., Scholes D., Stamm W. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. J. Am. Med. Assoc. 281:1999;736-738.
65. Manges A., Johnson J., Foxman B., O'Bryan T., Fullerton K., Riley L. Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group. New Engl. J. M. 345:2001;1007-1013.
66. Cheong H.J., Yoo C.W., Sohn J.W., Kim W.J., Kim M.J., Park S.C. Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea. Clin. Infect. Dis. 33:2001;48-53.
67. Wiener J., Quinn J., Bradford P., et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. J. Am. Med. Assoc. 281:1999;517-523.
68. Langermann S., Palaszynski S., Barnhart M., et al. Prevention of mucosal Escherichia coli infection by Fim-H-adhesin-based systemic vaccination. Science. 276:1997;607-611.
69. O'Hanley P. Prospects for urinary tract vaccines. Mobley H., Warren J. Urinary Tract Infections: Molecular Pathogenesis and Clinical Management. 1996;405-425 ASM Press, Washington, DC.
70. Stapleton A., Stamm W. Prevention of urinary tract infection. Infect. Dis. Clin. North Am. 11:1997;719-733.
71. Hagberg L., Leffler H., Svanborg-Eden C. Non-antibiotic prevention of urinary tract infection. Infection. 13:1985;196-200.
72. Svensson M., Lindstedt R., Radin N., Svanborg C. Epithelial glucosphingolipid expression as a determinant of bacterial adherence and cytokine production. Infect. Immun. 62:1994;4404-4410.